Treatment of Pediatric Patients That Lost Sense of Smell Due to COVID-19

• Status: Recruiting
• Trial end date: 2024-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This research study is a randomized controlled trial in pediatric and young adult patients who have lost their sense of smell due to COVID-19 viral infection. The goals are:

1. to learn more about the effects of smell retraining therapy on smell loss following COVID-19 and

2. to determine if budesonide-saline irrigations make smell retraining therapy more effective.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Amanda Stapleton
• Treatments: Budesonide; Glucocorticoids

Criteria

Inclusion Criteria:

• Subjects ages 6 to 21 who have loss of smell (anosmia) or dysosmia (disordered smell perception) and thought to have occurred due to COVID-19.

• Subjects who are able to complete the smell test (UPSIT), self-report their loss of smell, and do the assigned daily therapy.

Exclusion Criteria:

• Duration of anosmia or dysosmia <60 days

• Previous smell retraining

• Prior interventions for loss of smell (excluding those on Flonase and Azelastine)

• Contraindications for nasal budesonide treatment, as determined by the treating physician

• Active cigarette smoker or use of vapes

• Previous head trauma

• Congenital anosmia

• History of brain tumor

• Neurocognitive disorders

• Multiple sclerosis

• Seizure disorder

• Cystic fibrosis

• Primary Ciliary Dyskinesia

• History of nasal polyps

• Inability to self-report